MTAP and astrocytoma (excluding glioblastoma): This is in line with previous studies founding sensitivities between 59% and 100% and specificities between 96% and 100% for detection of homozygous deletion by MTAP IHC in urothelial bladder carcinomas, mesothelioma, astrocytoma, and meningioma (summarized in [18]).